how many people are on glp 1 take drugs GLP-1 Drugs Market Size to Hit USD 132.79 The GLP-1 Access Gap: Mapping

[DOI] [PMC free article] [PubMed] [Google Scholar] [148].Yu Pan C, Han P, Liu X, Yan S, Feng P, Zhou Z, Lv X, Tian H, Jin Kui Y, Su B, Shang S, Niemoeller E, Lixisenatide treatment improves glycaemic control in Asian patients with type 2 diabetes mellitus inadequately controlled on metformin with or without sulfonylurea: a randomized, double-blind, placebo-controlled, 24-week trial (GetGoal-M-Asia), Diabetes/metabolism research and reviews, 30 (2014) 726735

Dual GIP/GLP-1 agonists now represent the highest-revenue growth segment in the GLP-1 weight loss drug market at 18.4% CAGR , with tirzepatide generating USD 18.3 billion in 2025 revenue through Zepbound and Mounjaro surpassing Eli Lillys entire insulin franchise within two years of commercial launch

First, some brands file their own IPR petitions against competitor patents, creating precedents for narrow claim interpretations that also benefit their own portfolio

The researchers included only studies that reported a mean weight loss of 3 kg with GLP-1RA treatment, to ensure that significant post-cessation weight regain could be captured

The critical insight is that fat loss is often still occurring during a plateau